Primary and Secondary Prevention in Colorectal Cancer

References

• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43.
   PubMed Web of Science ®Google Scholar
• Haenszel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40: 43–68.
   PubMed Web of Science ®Google Scholar
• McMichael AJ, McCall MG, Hartshorne JM, Woodings TL. Patterns of gastro-intestinal cancer in European migrants to Australia: the role of dietary change. Int J Cancer 1980; 25: 431–7.
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Giles GG. Colorectal cancer. Cancer Survey 1994; 19–20: 77–98.
   Google Scholar
• Koo LC, Mang OW, Ho JH. An ecological study of trends in cancer incidence and dietary changes in Hong Kong. Nutr Cancer 1997; 28: 289–301.
   Google Scholar
• World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. 1997. 670 pp.
   Google Scholar
• Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91: 916–32.
   PubMedGoogle Scholar
• IARC. IARC handbooks of cancer prevention. Vol. 8. Fruits and vegetables. Lyon: International Agency for Research on Cancer; 2003.
   Google Scholar
• WHO. Diet, nutrition and the prevention of chronic diseases. Joint WHO/FAO Expert Consultation. WHO Technical Report Series No. 916, 2003.
   Google Scholar
• Bingham SA, Day NE, Luben R, et al. Dietary fibre in food is associated with protection against colorectal cancer: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Lancet 2003; 361: 1496–501.
   PubMed Web of Science ®Google Scholar
• Malila N, Virtamo J, Virtanen M, Albanes D, Tangrea JA, Huttunen JK. The effect of alpha-tocopherol and beta-carotene supplementation on colorectal adenomas in middle-aged male smokers. Cancer Epidemiol Biomarkers Prey 1999; 8: 489–93.
   PubMed Web of Science ®Google Scholar
• Albanes D, Malila N, Taylor PR, et al. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland). Cancer Causes Control 2000; 11: 197–205.
   PubMed Web of Science ®Google Scholar
• Bussey HJ, DeCosse JJ, Deschner EE, et al. A randomized trial of ascorbic acid in polyposis coli. Cancer 1982; 50: 1434–9.
   PubMed Web of Science ®Google Scholar
• IARC. IARC handbooks of cancer prevention. Vol. 1. Non-steroidal anti-inflammatory drugs. Lyon: International Agency for Research on Cancer; 1997. 202 pp.
   Google Scholar
• Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998; 128: 713–20.
   PubMed Web of Science ®Google Scholar
• Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883–90.
   PubMed Web of Science ®Google Scholar
• Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891–9.
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenoma-tous polyposis. N Engl J Med 2000; 342: 1946–52.
   PubMed Web of Science ®Google Scholar
• Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology 1994; 854–7.
   PubMed Web of Science ®Google Scholar
• Thorson AG, Lynch HT, Smyrk TC. Rectal cancer in FAP patients after sulindac. Lancet 1994; 343: 180.
   Google Scholar
• Lynch HT, Thorson AG, Smyrk T. Rectal cancer after prolonged sulindac chemoprevention. A case report. Cancer 1995; 75: 936–8.
   Google Scholar
• Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastro-enterology 1991; 101: 635–9.
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adeno-matous polyposis. N Engl J Med 1993; 328: 1313–6.
   PubMed Web of Science ®Google Scholar
• IARC. IARC handbooks of cancer prevention. Vol. 6. Weight control and physical activity. Lyon: International Agency for Research on Cancer; 2002. 315 pp.
   Google Scholar
• Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565–74.
   PubMed Web of Science ®Google Scholar
• Bianchini F, Kaaks R, Vainio H. Weight control and physical activity in cancer prevention. Obes Rev 2002; 3: 5–8.
   Google Scholar
• Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60: 91–106.
   PubMed Web of Science ®Google Scholar
• Kaaks R. Nutrition, energy balance and colon cancer risk: the role of insulin and insulin-like growth factor-I. IARC Sci Publ 2002; 156: 289–93.
   PubMedGoogle Scholar
• Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF- I, IGF-binding proteins, and breast cancer risk, in Northern and Southern Sweden. Cancer Causes Control 2002; 13: 307–16.
   PubMed Web of Science ®Google Scholar
• Commission on Chronic Illness. Chronic illness in the United States: prevention of chronic illness. Cambridge, Mass: Har-vard University Press; 1957.
   Google Scholar
• Mandel J, Bond J, Church T, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365–71.
   PubMed Web of Science ®Google Scholar
• Mandel J, Church T, Ederer F, et al. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91: 434–7.
   PubMed Web of Science ®Google Scholar
• Hardcastle JD, Chamberlain JO, Robinson MH, et al. Rando-mised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472–7.
   PubMed Web of Science ®Google Scholar
• Kronborg 0, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467–71.
   Google Scholar
• Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. Br Med J 1998; 317: 559–65.
   PubMed Web of Science ®Google Scholar
• Mandel J, Church T, Bond J, et al. The effect of fecal occult blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603–7.
   PubMed Web of Science ®Google Scholar
• Miller AB. Review of sigmoidoscopic screening for colorectal cancer. In: Chamberlain J, Miller AB, eds. Screening for gastrointestinal cancer. Toronto: Hans Huber; 1988. pp. 3–7.
   Google Scholar
• Selby JV, Friedman GD, Quesenberry CJ, et al. A case-control study of screening sigmoidoscopy and mortality from color-ectal cancer. N Engl J Med 1992; 326: 653–7.
   PubMed Web of Science ®Google Scholar
• Prorok PC, Bresalier RS, Chia D, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21: 273S–9S.
   Google Scholar
• Atkin W Screening for colorectal cancer: the heart of the matter. Gut 1999; 45: 480–1.
   PubMed Web of Science ®Google Scholar
• Senore C, Segnan N, Rossini F, et al. Screening for colorectal cancer by once-only sigmoidoscopy: a feasibility study in Turin, Italy. J Med Screen 1996; 3: 72–8.
   PubMedGoogle Scholar
• Winawer SJ, Zauber AG, O'Brien MJ, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329: 1977–81.
   Google Scholar
• Muller A, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. Ann Intern Med 1995; 123: 904–10.
   PubMed Web of Science ®Google Scholar
• Kavanagh A, Giovannucci E, Fuchs C, et al. Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control 1998; 9: 455–62.
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Washington: Department of Health and Human Services; 1996.
   Google Scholar
• Burn J, Chapman PD, Bishop DT, et al. Susceptibility markers in colorectal cancer. In: Miller AB, Bartsch H, Boffetta P, Dragsted L, Vainio H, eds. Biomarkers in cancer chemopreven-tion. Lyon: IARC Press; 2001. pp. 131–47.
   Google Scholar
• Vainio H, Bianchini F. Prevention of disease with pharmaceu-ticals. Pharmacol Toxicol 2001; 88: 111–8.
   PubMedGoogle Scholar
• Gilbertsen VA, Nelms JM. The prevention of invasive cancer of the rectum. Cancer 1978; 41: 1137–9.
   PubMed Web of Science ®Google Scholar
• Friedman GD, Collen MF, Fireman BH. Multiphasic health checkup evaluation: a 16-year follow-up. J Chron Dis 1986; 39: 453–63.
   Google Scholar
• Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658–62.
   Google Scholar
• Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84: 1572–5.
   PubMed Web of Science ®Google Scholar
• Thiis-Evensen E, Hoff G, Sauar J, et al. Population-based surveillance by colonoscopy: effect on the incidence of color-ectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999; 34: 414–20.
   Google Scholar